跳至主要内容
临床试验/EUCTR2018-003304-39-DK
EUCTR2018-003304-39-DK进行中(未招募)1 期

Efficacy of a novel 1l PEG plus ascorbate (Plenvu) bowel preparation vs. 2l PEG plus ascorbate (Moviprep), a randomized controlled multicenter trial

Morten Rasmussen0 个研究点目标入组 1,274 人开始时间: 2018年10月29日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
1,274

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Participants in the Danish national bowel cancer screening scheduled for colonoscopy at one of the two centres (Bispebjerg Hospital or Herlev Hospital
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 637
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 637

排除标准

  • Not able to understand, read or speak Danish
  • Not able to receive documents sent via e-Boks
  • Anticipated compliance problems
  • Hypersensitivity to the active substances in Moviprep or Plenvu
  • Gastrointestinal obstruction or perforation
  • Disorders of gastric emptying
  • Phenylketonuria
  • Glucose-6-phosphate dehydrogenase deficiency
  • Toxic megacolon
  • Severe chronic inflammatory bowel disease
  • Breastfeeding
  • Severe kidney impairment (creatinine clearance less than 30 ml/minute/1.73 m2
  • Cardiac failure (grade III or IV of NYHA)
  • Those at risk of arrhythmias
  • Dehydration

研究者

发起方
Morten Rasmussen

相似试验